Defining Transabdominal Intestinal Ultrasound Treatment Response and Remission in Inflammatory Bowel Disease : Systematic Review and Expert Consensus Statement
© The Author(s) 2021. Published by Oxford University Press on behalf of European Crohn’s and Colitis Organisation..
BACKGROUND AND AIMS: No consensus exists on defining intestinal ultrasound response, transmural healing, or transmural remission in inflammatory bowel disease, nor clear guidance for optimal timing of assessment during treatment. This systematic review and expert consensus study aimed to define such recommendations, along with key parameters included in response reporting.
METHODS: Electronic databases were searched from inception to July 26, 2021, using pre-defined terms. Studies were eligible if at least two intestinal ultrasound [IUS] assessments at different time points during treatment were reported, along with an appropriate reference standard. The QUADAS-2 tool was used to examine study-level risk of bias. An international panel of experts [n = 18] rated an initial 196 statements [RAND/UCLA process, scale 1-9]. Two videoconferences were conducted, resulting in additional ratings of 149 and 13 statements, respectively.
RESULTS: Out of 5826 records, 31 full-text articles, 16 abstracts, and one research letter were included; 83% [40/48] of included studies showed a low concern of applicability, and 96% [46/48] had a high risk of bias. A consensus was reached on 41 statements, with clear definitions of IUS treatment response, transmural healing, transmural remission, timing of assessment, and general considerations when using intestinal ultrasound in inflammatory bowel disease.
CONCLUSIONS: Response criteria and time points of response assessment varied between studies, complicating direct comparison of parameter changes and their relation to treatment outcomes. To ensure a unified approach in routine care and clinical trials, we provide recommendations and definitions for key parameters for intestinal ultrasound response, to incorporate into future prospective studies.
| Errataetall: | |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:16 |
|---|---|
| Enthalten in: |
Journal of Crohn's & colitis - 16(2022), 4 vom: 10. Mai, Seite 554-580 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ilvemark, Johan F K F [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Inflammatory bowel disease |
|---|
| Anmerkungen: |
Date Completed 12.05.2022 Date Revised 16.07.2022 published: Print CommentIn: J Crohns Colitis. 2021 Dec 18;:. - PMID 34922384 Citation Status MEDLINE |
|---|
| doi: |
10.1093/ecco-jcc/jjab173 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM331552183 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM331552183 | ||
| 003 | DE-627 | ||
| 005 | 20231225213723.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/ecco-jcc/jjab173 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1105.xml |
| 035 | |a (DE-627)NLM331552183 | ||
| 035 | |a (NLM)34614172 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ilvemark, Johan F K F |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Defining Transabdominal Intestinal Ultrasound Treatment Response and Remission in Inflammatory Bowel Disease |b Systematic Review and Expert Consensus Statement |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 12.05.2022 | ||
| 500 | |a Date Revised 16.07.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a CommentIn: J Crohns Colitis. 2021 Dec 18;:. - PMID 34922384 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © The Author(s) 2021. Published by Oxford University Press on behalf of European Crohn’s and Colitis Organisation. | ||
| 520 | |a BACKGROUND AND AIMS: No consensus exists on defining intestinal ultrasound response, transmural healing, or transmural remission in inflammatory bowel disease, nor clear guidance for optimal timing of assessment during treatment. This systematic review and expert consensus study aimed to define such recommendations, along with key parameters included in response reporting | ||
| 520 | |a METHODS: Electronic databases were searched from inception to July 26, 2021, using pre-defined terms. Studies were eligible if at least two intestinal ultrasound [IUS] assessments at different time points during treatment were reported, along with an appropriate reference standard. The QUADAS-2 tool was used to examine study-level risk of bias. An international panel of experts [n = 18] rated an initial 196 statements [RAND/UCLA process, scale 1-9]. Two videoconferences were conducted, resulting in additional ratings of 149 and 13 statements, respectively | ||
| 520 | |a RESULTS: Out of 5826 records, 31 full-text articles, 16 abstracts, and one research letter were included; 83% [40/48] of included studies showed a low concern of applicability, and 96% [46/48] had a high risk of bias. A consensus was reached on 41 statements, with clear definitions of IUS treatment response, transmural healing, transmural remission, timing of assessment, and general considerations when using intestinal ultrasound in inflammatory bowel disease | ||
| 520 | |a CONCLUSIONS: Response criteria and time points of response assessment varied between studies, complicating direct comparison of parameter changes and their relation to treatment outcomes. To ensure a unified approach in routine care and clinical trials, we provide recommendations and definitions for key parameters for intestinal ultrasound response, to incorporate into future prospective studies | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Systematic Review | |
| 650 | 4 | |a Intestinal ultrasound | |
| 650 | 4 | |a inflammatory bowel disease | |
| 650 | 4 | |a transmural healing | |
| 650 | 4 | |a transmural remission | |
| 650 | 4 | |a treatment response | |
| 700 | 1 | |a Hansen, Tawnya |e verfasserin |4 aut | |
| 700 | 1 | |a Goodsall, Thomas M |e verfasserin |4 aut | |
| 700 | 1 | |a Seidelin, Jakob B |e verfasserin |4 aut | |
| 700 | 1 | |a Al-Farhan, Heba |e verfasserin |4 aut | |
| 700 | 1 | |a Allocca, Mariangela |e verfasserin |4 aut | |
| 700 | 1 | |a Begun, Jakob |e verfasserin |4 aut | |
| 700 | 1 | |a Bryant, Robert V |e verfasserin |4 aut | |
| 700 | 1 | |a Carter, Dan |e verfasserin |4 aut | |
| 700 | 1 | |a Christensen, Britt |e verfasserin |4 aut | |
| 700 | 1 | |a Dubinsky, Marla C |e verfasserin |4 aut | |
| 700 | 1 | |a Gecse, Krisztina B |e verfasserin |4 aut | |
| 700 | 1 | |a Kucharzik, Torsten |e verfasserin |4 aut | |
| 700 | 1 | |a Lu, Cathy |e verfasserin |4 aut | |
| 700 | 1 | |a Maaser, Christian |e verfasserin |4 aut | |
| 700 | 1 | |a Maconi, Giovanni |e verfasserin |4 aut | |
| 700 | 1 | |a Nylund, Kim |e verfasserin |4 aut | |
| 700 | 1 | |a Palmela, Carolina |e verfasserin |4 aut | |
| 700 | 1 | |a Wilson, Stephanie R |e verfasserin |4 aut | |
| 700 | 1 | |a Novak, Kerri |e verfasserin |4 aut | |
| 700 | 1 | |a Wilkens, Rune |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of Crohn's & colitis |d 2007 |g 16(2022), 4 vom: 10. Mai, Seite 554-580 |w (DE-627)NLM204021901 |x 1876-4479 |7 nnns |
| 773 | 1 | 8 | |g volume:16 |g year:2022 |g number:4 |g day:10 |g month:05 |g pages:554-580 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/ecco-jcc/jjab173 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 16 |j 2022 |e 4 |b 10 |c 05 |h 554-580 | ||